{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:13:58Z","timestamp":1772813638238,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"am","delay-in-days":409,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.therap.2020.12.012","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T10:23:38Z","timestamp":1607855018000},"page":"455-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Profils d\u2019effets ind\u00e9sirables sous abirat\u00e9rone et enzalutamide\u00a0: analyse descriptive des donn\u00e9es de la base nationale de pharmacovigilance"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-9107","authenticated-orcid":false,"given":"Lucie-Marie","family":"Scailteux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Sassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-9478","authenticated-orcid":false,"given":"Louise","family":"Triquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.12.012_bib0330","series-title":"EAU guidelines: prostate cancer. Uroweb","author":"Mottet","year":"2020"},{"key":"10.1016\/j.therap.2020.12.012_bib0335","series-title":"Commission de la transparence_Avis_16\u00a0mai 2018_ abiraterone (Zytiga\u00ae)","author":"HAS","year":"2018"},{"key":"10.1016\/j.therap.2020.12.012_bib0340","series-title":"Commission de la transparence_Avis_12\u00a0juin 2019_Enzalutamide (Xtandi\u00ae)","author":"HAS","year":"2019"},{"issue":"13","key":"10.1016\/j.therap.2020.12.012_bib0345","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/fon-2018-0940","article-title":"Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer","volume":"15","author":"Sternberg","year":"2019","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.therap.2020.12.012_bib0350","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1756287218786160","article-title":"Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of \u201creal-life\u201d studies","volume":"10","author":"Marchioni","year":"2018","journal-title":"Ther Adv Urol"},{"issue":"9","key":"10.1016\/j.therap.2020.12.012_bib0355","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14740338.2019.1648428","article-title":"A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer","volume":"18","author":"Castellan","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2020.12.012_bib0360","series-title":"Zytiga\u00ae \u2014\u00a0r\u00e9sum\u00e9 des caract\u00e9ristiques du produit","year":"2020"},{"key":"10.1016\/j.therap.2020.12.012_bib0365","series-title":"Summary of risk management plan for XTANDI","year":"2020"},{"key":"10.1016\/j.therap.2020.12.012_bib0370","series-title":"Xtandi\u00ae \u2014\u00a0r\u00e9sum\u00e9 des caract\u00e9ristiques du produit","year":"2020"},{"issue":"6","key":"10.1016\/j.therap.2020.12.012_bib0375","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel anti-androgen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.therap.2020.12.012_bib0380","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.therap.2020.12.012_bib0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1756287214555336","article-title":"An update on enzalutamide in the treatment of prostate cancer","volume":"7","author":"Merseburger","year":"2015","journal-title":"Ther Adv Urol"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0390","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41391-019-0195-5","article-title":"A review of prostate cancer treatment impact on the CNS and cognitive function","volume":"23","author":"Ryan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.therap.2020.12.012_bib0395","first-page":"431","article-title":"A case of castration-resistant prostate cancer with fatal convulsive seizure after administration of enzalutamide","volume":"63","author":"Iwanishi","year":"2017","journal-title":"Hinyokika Kiyo"},{"issue":"1","key":"10.1016\/j.therap.2020.12.012_bib0400","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/iju5.12025","article-title":"Enzalutamide-induced severe thrombocytopenia complicated by a seizure in a 76-year-old man with castration-resistant prostate cancer","volume":"2","author":"Murata","year":"2019","journal-title":"IJU Case Rep"},{"issue":"5","key":"10.1016\/j.therap.2020.12.012_bib0405","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaoncol.2017.3361","article-title":"Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study","volume":"4","author":"Slovin","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.therap.2020.12.012_bib0410","first-page":"143","article-title":"Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy","volume":"10","author":"Pilon","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"10.1016\/j.therap.2020.12.012_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2019.07.017","article-title":"Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT)","volume":"17","author":"Shore","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.therap.2020.12.012_bib0420","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance \u2013 the next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0425","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0430","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0435","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.therap.2020.12.012_bib0440","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Statistician"},{"key":"10.1016\/j.therap.2020.12.012_bib0445","series-title":"ameli.fr \u2014\u00a0Medic\u2019AM\u00a0\u2014 m\u00e9dicaments d\u00e9livr\u00e9s par les pharmacies de ville par type de prescripteur","author":"L\u2019Assurance maladie","year":"2020"},{"key":"10.1016\/j.therap.2020.12.012_bib0450","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2016.04.002","article-title":"Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials","volume":"61","author":"Roviello","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.therap.2020.12.012_bib0455","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","article-title":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17\u00a0inhibitors: a meta-analysis of published trials","volume":"101","author":"Roviello","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0460","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14737140.2018.1419871","article-title":"Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis","volume":"18","author":"Zhu","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"48","key":"10.1016\/j.therap.2020.12.012_bib0465","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"Moreira","year":"2017","journal-title":"Oncotarget"},{"issue":"44","key":"10.1016\/j.therap.2020.12.012_bib0470","doi-asserted-by":"crossref","first-page":"e17748","DOI":"10.1097\/MD.0000000000017748","article-title":"Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"98","author":"Zheng","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0475","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41391-019-0182-x","article-title":"Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies","volume":"23","author":"De Nunzio","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"13","key":"10.1016\/j.therap.2020.12.012_bib0480","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","article-title":"Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes","volume":"140","author":"Salem","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.therap.2020.12.012_bib0485","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.acvd.2019.06.008","article-title":"Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: a review and pharmacovigilance study","volume":"112","author":"Salem","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.therap.2020.12.012_bib0490","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","article-title":"Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study","volume":"113","author":"Bretagne","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.therap.2020.12.012_bib0495","first-page":"479","article-title":"A case of fulminant hepatitis after administration of abiraterone acetate","volume":"63","author":"Yumiba","year":"2017","journal-title":"Hinyokika Kiyo"},{"issue":"4","key":"10.1016\/j.therap.2020.12.012_bib0500","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1097\/MJT.0000000000000597","article-title":"Abiraterone-associated fulminant liver failure","volume":"25","author":"Singh","year":"2018","journal-title":"Am J Ther"},{"issue":"1","key":"10.1016\/j.therap.2020.12.012_bib0505","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cld.2016.08.004","article-title":"Epidemiology and genetic risk factors of drug hepatotoxicity","volume":"21","author":"Ahmad","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.therap.2020.12.012_bib0510","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12882-015-0113-6","article-title":"Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report","volume":"16","author":"Neyra","year":"2015","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0515","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1078155215620921","article-title":"Abiraterone-induced rhabdomyolysis: a case report","volume":"23","author":"Moore","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.therap.2020.12.012_bib0520","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1078155217701294","article-title":"Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: a case report and review of the literature","volume":"24","author":"Dineen","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.therap.2020.12.012_bib0525","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/STROKEAHA.115.012004","article-title":"Atrial fibrillation and mechanisms of stroke: time for a new model","volume":"47","author":"Kamel","year":"2016","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.therap.2020.12.012_bib0530","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1758834016656493","article-title":"Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors","volume":"8","author":"Verzoni","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.therap.2020.12.012_bib0535","series-title":"Thesaurus des interactions m\u00e9dicamenteuses","author":"ANSM","year":"2020"},{"issue":"6","key":"10.1016\/j.therap.2020.12.012_bib0540","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/17425255.2015.1041918","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer","volume":"11","author":"Han","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.therap.2020.12.012_bib0545","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2020.12.012_bib0550","series-title":"Traitement par antivitamines K (AVK)\u00a0: nouvelles informations \u2014\u00a0lettre aux professionnels de sant\u00e9\u00a0\u2014 ANSM\u00a0: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","year":"2018"},{"issue":"9","key":"10.1016\/j.therap.2020.12.012_bib0555","first-page":"3209","article-title":"Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone+prednisone","volume":"27","author":"Dubinsky","year":"2019","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.therap.2020.12.012_bib0560","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","article-title":"Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide","volume":"55","author":"Benoist","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.therap.2020.12.012_bib0565","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1080\/15563650.2018.1469758","article-title":"Enzalutamide and analytical interferences in digoxin assays","volume":"56","author":"Deguigne","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"7","key":"10.1016\/j.therap.2020.12.012_bib0570","doi-asserted-by":"crossref","first-page":"e007008","DOI":"10.1161\/CIRCHEARTFAILURE.120.007008","article-title":"Falsely elevated digoxin levels in patients on enzalutamide","volume":"13","author":"Kalra Dinesh","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.therap.2020.12.012_bib0575","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2017.11.016","article-title":"Difficulties in pain management using oxycodone and fentanyl in enzalutamide-treated patients with advanced prostate cancer","volume":"55","author":"Westdorp","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0580","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","article-title":"The combination of enzalutamide and opioids: a painful pitfall?","volume":"75","author":"Benoist","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.therap.2020.12.012_bib0585","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00228-015-2005-x","article-title":"Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients","volume":"72","author":"Oosten","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.therap.2020.12.012_bib0590","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/0284186X.2019.1606936","article-title":"First-time prescription of enzalutamide in a patient treated with fluindione and digoxin: serial drug interactions","volume":"58","author":"Strobbe","year":"2019","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.therap.2020.12.012_bib0595","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.therap.2020.12.012_bib0600","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JOP.2017.022004","article-title":"Management of anticoagulation in patients with prostate cancer receiving enzalutamide","volume":"13","author":"Shatzel","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.therap.2020.12.012_bib0605","article-title":"Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies","author":"Brunckhorst","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"24","key":"10.1016\/j.therap.2020.12.012_bib0610","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1002\/cncr.29672","article-title":"Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners","volume":"121","author":"Donovan","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.therap.2020.12.012_bib0615","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.juro.2017.08.080","article-title":"Efficacy and safety of enzalutamide vs bicalutamide in younger and older patients with metastatic castration resistant prostate cancer in the TERRAIN trial","volume":"199","author":"Siemens","year":"2018","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.therap.2020.12.012_bib0620","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.therap.2020.12.012_bib0625","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.therap.2020.12.012_bib0630","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.therap.2020.12.012_bib0635","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ejhf.284","article-title":"National trends in rate of patients hospitalized for heart failure and heart failure mortality in France, 2000\u20132012","volume":"17","author":"Gabet","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.therap.2020.12.012_bib0640","series-title":"Insuffisance cardiaque","author":"Sant\u00e9 publique France","year":"2019"},{"key":"10.1016\/j.therap.2020.12.012_bib0645","series-title":"Groupe de travail \u00ab\u00a0\u00c9tudes \u00e9pid\u00e9miologiques des produits de sant\u00e9\u00a0\u00bb No\u00a09 (GT022018031)","author":"ANSM","year":"2018"},{"issue":"2","key":"10.1016\/j.therap.2020.12.012_bib0325","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.therap.2018.08.001","article-title":"What is pharmacoepidemiology? Definition, methods, interest and clinical applications","volume":"74","author":"Montastruc","year":"2019","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720302298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720302298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:21Z","timestamp":1758567261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720302298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0040595720302298"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.12.012","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profils d\u2019effets ind\u00e9sirables sous abirat\u00e9rone et enzalutamide\u00a0: analyse descriptive des donn\u00e9es de la base nationale de pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}